Novo posts trial win for sickle cell disease drug (NVO:NYSE)
Summary
Novo Nordisk (NVO) stock is in focus as the Phase 3 HIBISCUS trial for sickle cell disease therapy etavopivat succeeds. Read more here.
Description
Novo Nordisk (NVO) stock is in focus as the Phase 3 HIBISCUS trial for sickle cell disease therapy etavopivat succeeds. Read more here.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source